Novel combination approaches for myeloma:reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.02.008
- VernacularTitle:多发性骨髓瘤的新药治疗方案：第57届美国血液学会年会报道
- Author:
Yuanyuan YU
;
Zhongxia HUANG
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
New drugs;
Response;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(2):89-93
- CountryChina
- Language:Chinese
-
Abstract:
As understanding the biology of multiple myeloma (MM) and application of new drugs, regimens containing new drugs deepened therapeutic response and prolonged the survival of MM patients. This article updates the therapeutic response of regimens reported in the 57th American Society of Hematology annual meeting, containing immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors and other new drugs including monoclonal antibodies and the others. In the same time, minimal residual disease (MRD) is also used to evaluate the remission depth of MM. In order to achieve durable long-term remission and higher quality of life, new drug combination regimens have been recommended, especially for the relapsed or the high risk MM patients.
